679 related articles for article (PubMed ID: 17963208)
1. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
2. Delivery of anticancer drugs.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
4. Advances in polymeric micelles for drug delivery and tumor targeting.
Kedar U; Phutane P; Shidhaye S; Kadam V
Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
[TBL] [Abstract][Full Text] [Related]
5. Targeting of drugs to cell surface receptors.
Ríhová B
Crit Rev Biotechnol; 1997; 17(2):149-69. PubMed ID: 9192475
[TBL] [Abstract][Full Text] [Related]
6. Prodrug activation enzymes in cancer gene therapy.
Aghi M; Hochberg F; Breakefield XO
J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
[TBL] [Abstract][Full Text] [Related]
7. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Gopin A; Pessah N; Shamis M; Rader C; Shabat D
Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
[No Abstract] [Full Text] [Related]
8. Liposomal cancer therapy: exploiting tumor characteristics.
Kaasgaard T; Andresen TL
Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
[TBL] [Abstract][Full Text] [Related]
9. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
10. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
[TBL] [Abstract][Full Text] [Related]
11. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
12. Do prodrugs deliver?
Smith DA
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853
[TBL] [Abstract][Full Text] [Related]
13. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.
Yokoyama M
Expert Opin Drug Deliv; 2010 Feb; 7(2):145-58. PubMed ID: 20095939
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs: design and clinical applications.
Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Järvinen T; Savolainen J
Nat Rev Drug Discov; 2008 Mar; 7(3):255-70. PubMed ID: 18219308
[TBL] [Abstract][Full Text] [Related]
15. Design of anticancer prodrugs for reductive activation.
Chen Y; Hu L
Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
[TBL] [Abstract][Full Text] [Related]
16. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.
Majumdar S; Duvvuri S; Mitra AK
Adv Drug Deliv Rev; 2004 Jun; 56(10):1437-52. PubMed ID: 15191791
[TBL] [Abstract][Full Text] [Related]
17. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
18. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Andresen TL; Jensen SS; Jørgensen K
Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
[TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
Dubowchik GM; Walker MA
Pharmacol Ther; 1999 Aug; 83(2):67-123. PubMed ID: 10511457
[TBL] [Abstract][Full Text] [Related]
20. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]